Regardless of this FEV0.4/FVC difference in clinical correlations to the CFTR-F508del ferret model, PFT endpoints may serve as useful endpoints for therapeutic studies in the model, and with the exception of the FEV0.4/FVC ratio, these PFT endpoints reasonably correlated with disease progression in people with CF. This evidence concerns the gene CFTR and cystic fibrosis.